Equillium (EQ) Revenue & Revenue Breakdown
Equillium Revenue Highlights
Latest Revenue (Y)
$41.09M
Latest Revenue (Q)
$4.39M
Equillium Revenue by Period
Equillium Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $41.09M | 13.89% |
| 2023-12-31 | $36.08M | 128.97% |
| 2022-12-31 | $15.76M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Equillium generated $41.09M in revenue during NA 2024, up 13.89% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Equillium Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $4.39M | -63.88% |
| 2024-09-30 | $12.16M | -12.21% |
| 2024-06-30 | $13.85M | 29.60% |
| 2024-03-31 | $10.69M | 16.05% |
| 2023-12-31 | $9.21M | 3.84% |
| 2023-09-30 | $8.87M | -2.78% |
| 2023-06-30 | $9.12M | 2.76% |
| 2023-03-31 | $8.88M | -43.66% |
| 2022-12-31 | $15.76M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | - |
Equillium generated $4.39M in revenue during Q4 2024, up -63.88% compared to the previous quarter, and up 49.52% compared to the same period a year ago.
Equillium Revenue Breakdown
Equillium Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 |
|---|---|
| Upfront Payment Amortization | $1.00M |
Latest
Equillium's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Upfront Payment Amortization (100.00%).
Equillium Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CHRS | Coherus BioSciences | $266.96M | $7.60M |
| SPRO | Spero Therapeutics | $47.98M | $9.36M |
| EQ | Equillium | $41.09M | $4.39M |
| BOLT | Bolt Biotherapeutics | $7.69M | $1.22M |
| CUE | Cue Biopharma | $5.49M | $421.00K |
| SABS | SAB Biotherapeutics | $2.24M | $114.70K |
| HOWL | Werewolf Therapeutics | $1.89M | - |
| LYRA | Lyra Therapeutics | $1.53M | $209.00K |
| IKNA | Ikena Oncology | - | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| ANTX | AN2 Therapeutics | - | - |
| BCAB | BioAtla | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| TRVI | Trevi Therapeutics | - | - |
| HOOK | HOOKIPA Pharma | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| JSPR | Jasper Therapeutics | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| KTTA | Pasithea Therapeutics | - | - |